case_images: PMC11324257_01
case_images: PMC11324257_02
case_images: PMC11324257_03
case_images: PMC11324257_04
case_images: a Multiple small and large enhancing lesions along the sulci and surfaces of the cerebellar hemispheres are observed. In addition, enhancing nodules in the cerebral sickle cells are noted. b Multiple progressively increasing and enlarging metastases in both lobes of the liver are observed. c No contrast nodules and no recurrence within the left breast are observed.
case_images: cro-2024-0017-0001-540257_F01.jpg
case_images: PMC11324257_04_cro-2024-0017-0001-540257_F01.jpg
case_images: F1
case_images: The scans were indicative of BM exacerbation (Fig. 1a) and the progression of liver metastases (Fig. 1b). However, no recurrence of the primary lesion was observed (Fig. 1c).
case_images: PMC11324257_05
case_images: Course of treatment. a Emergency visit for impaired consciousness and received WBRT. b BCBM and liver metastases achieved PR with capecitabine treatment. c Emergency visit for absence seizures and olaparib initiated. d BCBM achieved PR, (e) BCBM achieved CR and liver metastases achieved PR. f BCBM achieved CR and liver metastases progressed. WBRT, whole-brain radiotherapy; BCBM, breast cancer brain metastasis; PR, partial response; SD, stable disease; CR, complete response.
case_images: cro-2024-0017-0001-540257_F02.jpg
case_images: PMC11324257_05_cro-2024-0017-0001-540257_F02.jpg
case_images: F2
case_images: However, 9 months after the initiation of treatment with olaparib, liver metastases progressed, and olaparib was replaced by eribulin, although a whole-brain MRI still revealed a CR of BM to olaparib (Fig. 2).